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Burdens	Beget	Burden:		Examining	the	Physiological	Links	Between	Psychological	Stress	and	Cardiovascular	Disease	
	
Abstract	
Introduction	Psoriasis	is	a	chronic	inflammatory	disorder	associated	with	both	cardiovascular	disease	and	mood	disorders	such	as	depression	and	anxiety.		Multiple	behavioral	and	physiological	processes	link	depression,	psoriasis	and	atherosclerosis,	but	inflammation	is	a	major	player	implicated	in	the	pathogenesis	of	all	three.		Psoriasis	is	associated	with	vascular	inflammation,	measured	by	18F-fluorodeoxyglucose	positron	emission	tomography/computed	tomography	(FDG	PET/CT),	and	an	increased	risk	of	myocardial	infarction.		Vascular	inflammation	by	FDG	PET/CT	predicts	cardiovascular	risk	and	outcomes.		Studies	have	also	shown	that	patients	with	psoriasis	are	more	likely	to	suffer	from	comorbid	depression	and	anxiety.		However,	whether	these	comorbidities	may	accelerate	the	development	of	cardiovascular	disease	in	psoriasis	is	not	well-characterized.		
Hypothesis	Our	primary	hypothesis	is	that	aortic	vascular	inflammation	and	coronary	plaque	burden	will	be	increased	in	patients	with	psoriasis	who	have	depression	when	compared	to	psoriasis	patients	who	do	not.		In	a	follow-up	study	we	hypothesize	that	metabolic	activity	in	the	anatomic	location	of	the	amygdala	will	correlate	with	increased	vascular	inflammation	and	decreased	vascular	function.				
Methods	An	ongoing	psoriasis	study	cohort	was	chosen	for	the	patient	population.	Patients	who	reported	a	history	of	depression	(n=36)	on	survey	were	matched	by	age	and	sex	to	patients	who	reported	no	history	of	psychiatric	illness	(n=36).		FDG	PET/CT	scans	were	used	to	assess	vascular	inflammation.		From	these	scans,	standardized	uptake	values	were	calculated	by	analyzing	axial	slices	of	the	aorta.		Target-to-background	ratios	were	then	calculated	to	standardize	for	background	luminal	FDG	uptake.		Coronary	computed	tomography	angiography	scans	were	analyzed	in	order	to	determine	coronary	plaque	composition	and	to	quantify	plaque	burden.		Multivariate	linear	regression	analyses	were	performed	to	understand	the	potential	effect	of	psychiatric	diagnoses	on	aortic	vascular	inflammation	and	coronary	plaque	burden.		Traditional	cardiovascular	risk	factors	were	adjusted	for	(standardized	β	reported).		In	a	follow-up	study,	metabolic	activity	of	the	amygdala	was	quantified	via	analysis	of	FDG	uptake	in	the	anatomic	location	of	the	amygdala.		These	uptake	values	were	divided	by	FDG	uptake	in	the	adjacent	ipsilateral	temporal	lobe	for	standardization.		Target-to-background	ratios	were	then	used	to	quantify	amygdala	activity.		Vascular	function	was	studied	via	aortic	distensibility.		Using	phase	contrast	MRI	scans	throughout	the	duration	of	one	cardiac	cycle,	axial	slices	of	the	aorta	were	analyzed	to	calculate	aortic	distensibility.	
 
Results	Aortic	vascular	inflammation	and	coronary	plaque	burden	were	increased	in	psoriasis	patients	with	comorbid	depression	as	compared	to	those	without.		After	
adjustment	for	Framingham	Risk	Score,	vascular	inflammation	(β=0.26,	p=0.02),	total	plaque	burden	(β=0.17,	p=0.03),	and	non-calcified	plaque	burden	(β=0.17,	p=0.03)	associated	with	comorbid	depression.		In	a	subsequent	study,	patients	with	comorbid	depression	and/or	anxiety	had	higher	left	amygdala	activity.		In	unadjusted	analyses	vascular	inflammation	significantly	associated	with	amygdala	activity,	although	this	relationship	did	not	retain	significance	after	adjustment	for	traditional	cardiovascular	risk.		Aortic	distensibility	was	significantly	and	inversely	associated	with	left	amygdala	activity	both	in	unadjusted	analyses	and	after	adjustment	for	traditional	cardiovascular	risk.		
Conclusions	Patients	with	psoriasis	who	suffer	from	comorbid	depression	have	greater	burden	of	subclinical	cardiovascular	disease.		Furthermore,	vascular	function	is	reduced	in	these	patients	and	correlates	with	the	degree	of	activity	in	the	amygdala,	a	region	of	the	brain	that	plays	an	important	role	in	the	modulation	of	stress.		Targeted	assessment	of	psychological	stress	and	mood	disorders	in	psoriasis	patients	may	be	warranted	for	further	cardiovascular	risk	reduction	in	this	high-risk	population.		
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Introduction	
The	Epidemiology	of	Coronary	Artery	Disease	In	the	modern	era,	cardiovascular	disease	has	emerged	as	a	leading	cause	of	morbidity	and	mortality	in	the	United	States	and	around	the	world.		Despite	major	advancements	in	medicine,	technology,	and	healthcare	delivery	resulting	in	decreased	overall	burden	of	disease	and	greater	life	expectancy,	much	of	these	gains	have	come	from	improvements	in	treatment	and	prevention	in	other	major	fields	such	as	oncology	and	infectious	diseases.		Better	understanding	of	vascular	biology,	structural	heart	disease	and	cardiovascular	risk	factors	in	the	1900s	have	also	contributed	to	better	preventive	care	and	management,	but	such	improvements	have	been	modest	in	comparison.		Throughout	the	last	and	current	centuries,	cardiovascular	diseases	have,	as	an	aggregate,	caused	the	greatest	mortality	and	disability	in	the	United	States.	It	is	estimated	that	one	in	every	three	Americans	dies	from	cardiovascular	disease.	In	2013	in	the	United	States,	NHANES	data	demonstrated	an	annual	mortality	rate	of	222.9	per	100,000	persons.(1)		Mortality	rates	differed	significantly	by	race,	gender,	and	age.		Lowest	mortality	was	seen	among	Hispanic	women,	with	a	rate	of	136.4	per	100,000	persons,	while	mortality	rates	for	non-Hispanic	white	women	and	non-Hispanic	black	women	were	183.8	and	246.6	per	100,000	persons,	respectively.		Among	men,	death	rates	were	197.4,	270.6	and	356.7	per	100,000	persons	for	Hispanics,	whites	and	blacks,	respectively.		Overall,	mortality	among	men	was	269.8	per	100,000	as	compared	to	a	rate	of	184.8	per	100,000	in	women.		An	estimated	65%	of	all	cardiovascular	deaths	within	that	year	occurred	in	individuals	age	75	years	and	older.	
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Cardiovascular	disease	is	an	overarching	classification	that	comprises	stroke,	coronary	heart	disease,	peripheral	vascular	disease,	congenital	heart	disease,	valvular	heart	disease,	arrhythmias,	and	heart	failure.		Within	cardiovascular	disease,	coronary	heart	disease	is	a	major	contributor	to	disease	burden,	disability	and	mortality.		According	to	the	data	from	NHANES	2013,	coronary	heart	disease	is	present	in	about	6.2%	of	the	U.S.	population	age	20	years	and	older.		Roughly	1	out	of	7	deaths	are	attributable	to	coronary	heart	disease	and	a	myocardial	infarction	event	is	estimated	to	occur	once	every	42	seconds.		
Inflammation	and	Atherosclerosis	In	the	early	1900s	the	prevailing	thought	among	physicians	and	medical	scientists	was	that	the	heart	was	untouchable.		The	esteemed	surgeon	Sir	Stephen	Paget	once	said,	“no	new	method,	and	no	new	discovery,	can	overcome	the	natural	difficulties	
that	attend	a	wound	of	the	heart”.		Yet,	in	the	summer	of	1929,	a	young	German	physician	by	the	name	of	Werner	Forssmann	had	a	bold	idea	to	access	the	human	heart	via	a	long	ureteral	catheter.		So	determined	was	he	to	bring	this	idea	to	fruition	that,	enlisting	the	help	of	a	surgical	nurse,	he	arranged	to	serve	as	his	own	first	subject.		With	this	first	attempt,	he	achieved	a	successful	procedure	and	ultimately	ushered	in	a	new	wave	of	capabilities	for	diagnosing	and	treating	heart	disease.			 In	line	with	advancements	in	procedural	and	imaging	techniques,	our	understanding	of	the	natural	history	of	atherosclerosis	and	its	causal	factors	has	grown	significantly.		Our	knowledge	of	the	pathways	that	mediate	atherosclerosis	and	its	progression	towards	cardiovascular	events	has	expanded	considerably	in	recent	
3	
decades,	increasing	our	ability	to	provide	better	preventive	care	alongside	interventional	management.		Where	we	once	thought	of	atherosclerotic	plaque	development	as	arising	from	the	gradual	accumulation	of	lipids	in	the	vessel	wall,	we	now	understand	this	process	to	be	driven	by	a	concert	of	interconnected	immunologic	pathways	encompassing	both	innate	and	adaptive	systems,	as	evidenced	by	the	activity	of	monocytes,	macrophages,	T	cells	and	B	cells,	and	by	increases	in	inflammatory	mediators	such	as	M-CSF	and	C-reactive	protein	(see	Figure	1).(2)	
	
Figure	1:		Monocyte	and	Macrophage	Activity	in	Atherosclerosis	
	
	 	There	is	a	large,	multi-disciplinary	body	of	evidence	to	support	the	prominent	role	of	inflammation	in	cardiovascular	disease.		Epidemiologic	studies	of	chronic	inflammatory	diseases	such	as	systemic	lupus	erythematosus,	rheumatoid	arthritis,	and	
Monocytes	migrate	through	the	endothelium	and	become	macrophages.		Once	activated,	macrophages	release	several	pro-inflammatory	and	pro-thrombotic	mediators	that	promote	atherosclerotic	plaque	formation	and	progression.		
Reprinted	from	Libby	P.		Inflammation	in	Atherosclerosis.		Nature.		2002;	420:	868-874.	
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psoriasis	have	been	shown	to	increase	the	risk	of	myocardial	infarction,	stroke	and	cardiovascular	death.(3,4)		In	these	chronic	conditions,	systemic	inflammation	is	known	to	promote	the	up-regulation	of	both	innate	and	adaptive	immune	pathways,	leading	to	pro-inflammatory	cytokine	expression,	endothelial	activation,	vascular	inflammation,	and	disordered	lipid	metabolism.		The	relationship	of	these	atherogenic	processes	to	disease	severity	exhibit	dose-dependent	responses,	further	supporting	a	key	causal	role	for	inflammation	in	atherosclerosis.(5)		In	many	cases,	specific	immunologic	markers	have	been	directly	implicated	in	atherogenesis	using	the	human	clinical	models	provided	by	chronic	inflammatory	diseases.(6)		 These	insights	extend	to	the	general	population	as	markers	of	inflammation,	such	as	High-sensitivity	C-reactive	protein	and	Glycoprotein	A,	are	seen	to	correlate	with	cardiovascular	disease	in	healthy	volunteers.(7)		After	statin	therapy,	improvements	seen	in	these	inflammatory	markers	demonstrate	a	direct	relationship	with	improvement	in	cardiovascular	disease	risk.(8)		Although	statins	were	originally	created	for	the	purpose	of	reducing	cholesterol	via	inhibition	of	the	enzyme,	HMG-CoA	reductase,	the	anti-inflammatory	activities	of	statins	have	become	well-understood,	particularly	with	regards	to	their	ability	to	reduce	the	risk	of	cardiovascular	events	independent	of	cholesterol	reduction.(9)		Similarly,	aspirin,	prescribed	primarily	for	its	anti-thrombotic	properties,	is	also	known	to	exhibit	anti-inflammatory	effects.		However,	apart	from	statins	and	aspirin,	whose	anti-inflammatory	roles	were	discovered	secondarily,	there	are	currently	no	other	anti-inflammatory	drugs	in	use	in	the	general	population	for	the	treatment	and	prevention	of	cardiovascular	disease.		We	continue	to	rely	primarily	on	statins	and	other	lipid-lowering	and	anti-thrombotic	
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drugs	to	reduce	cardiovascular	risk,	despite	mounting	evidence	that	inflammatory	mediators	play	a	major	role	in	promoting	atherosclerosis.	Putting	together	our	advancing	understanding	of	the	way	inflammation	drives	atherosclerosis	with	the	associations	between	immune	modulation	and	cardiovascular	risk	seen	in	observational	studies,	it	has	become	clear	that	targeted	anti-inflammatory	therapies	hold	promise	for	preventing	and	slowing	the	pace	of	atherosclerotic	plaque	formation.		Towards	this	end,	there	are	three	major	trials	currently	evaluating	the	potential	use	of	immunomodulatory	drugs	to	treat	coronary	artery	disease.		Two	of	these	trials	look	specifically	at	low-dose	methotrexate	(TETHYS	and	CIRT)	and	the	third	studies	canakinumab,	a	human	monoclonal	antibody	against	interleukin-1beta	(CANTOS).(10,	11,	12	)	Results	from	these	studies	may	provide	new	treatment	options	for	secondary	prevention	of	cardiovascular	disease	in	high-risk	patients.		 Despite	these	encouraging	strides,	the	march	towards	viable	anti-inflammatory	therapies	for	heart	disease	has	been	slow	and	steady,	particularly	in	translating	novel	strategies	from	basic	science	and	pre-clinical	studies	into	human	clinical	trials.		For	example,	researchers	in	nanomedicine	have	developed	methods	for	specifically	localizing	delivery	of,	IL-10,	a	potent	anti-inflammatory	mediator,	to	atherosclerotic	plaques	and	have	been	able	to	demonstrate	plaque	reduction	and	stabilization	in	preclinical	models.(13)		If	this	work	can	be	successfully	extended	to	humans,	such	targeted	therapies	will	utilize	the	body’s	own	intricate	immune	signaling	pathways	to	isolate	and	treat	vascular	disease	at	its	source.		However,	many	challenges,	including	differences	between	the	way	atherosclerosis	progresses	in	humans	versus	animal	models,	complicate	the	road	to	discovery	in	this	arena.	
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On	a	different	front,	novel	anti-interleukin	therapies	are	currently	being	studied	in	patients	with	chronic	inflammatory	diseases	to	determine	whether	opposing	inflammation	will	lead	to	improved	cardiovascular	outcomes.(14)		We	stand	to	gain	valuable	information	from	these	trials	that	may	be	transferrable	to	the	general	population.	The	importance	of	developing	targeted	therapies	for	the	reduction	of	cardiovascular	disease	has	not	gone	unnoticed.		In	collaboration	with	the	major	biotechnology	companies,	Verily	Life	Sciences	and	AstraZeneca,	the	American	Heart	Association	recently	launched	an	initiative	known	as	“One	Brave	Idea”	to	incentivize	and	fund	research	towards	finding	the	cure	for	coronary	heart	disease.		It	is	a	lofty	endeavor,	but	one	that	will	be	met	with	an	equally	impressive	financial	commitment	of	75	million	dollars	pledged	to	the	selected	team.	Given	that	cardiovascular	disease	is	the	world’s	leading	cause	of	mortality,	the	translation	of	pharmacologic	anti-inflammatory	therapies	from	the	laboratory	to	the	clinic	represents	a	pressing	challenge	for	modern	medicine.		We	now	possess	the	appropriate	basic	science	foundation	to	allow	for	the	creation	of	medical	therapies	to	better	treat	and	prevent	cardiovascular	disease	by	directly	attacking	its	underlying	inflammatory	pathways.		Clinically	available	targeted	anti-inflammatory	therapies	for	the	primary	and	secondary	prevention	of	coronary	artery	disease	are	hopefully	not	far	beyond	the	horizon.				
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Psoriasis	as	a	Human	Clinical	Model	of	Atherosclerosis	Psoriasis	is	a	chronic	inflammatory	skin	disorder	that	affects	roughly	3.15%	of	the	U.S.	adult	population.(15)		An	estimated	17%	of	these	patients	suffer	from	moderate	to	severe	disease	as	defined	by	3%	or	greater	body	surface	area	affected.		Similar	to	atherosclerosis,	the	pathogenesis	of	psoriasis	involves	both	the	innate	and	adaptive	immune	pathways.		The	activity	of	macrophages(16),	neutrophils(17)	and	dendritic	cells(18)	are	increased	in	psoriasis	patients.		Dendritic	cells	then	signal	for	the	accumulation	and	differentiation	of	T	cells,	which	are	known	to	release	key	cytokines	responsible	for	mediating	skin	pathology.		In	particular,	TNF-alpha,	IL-17,	IL-12	and	IL-23	play	major	roles	in	the	development	of	psoriatic	lesions	and	have	been	the	focus	of	targeted	therapies.		Biologic	therapies	opposing	several	of	these	key	mediators	have	been	approved	for	the	treatment	of	moderate-to-severe	psoriasis.		Table	1	provides	a	list	of	FDA	approved	psoriasis	therapies	along	with	their	immunologic	targets.											
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Table	1:		Systemic	and	Biologic	Psoriasis	Therapies	
Drug	Class	 Drug	Names	 Mechanism	of	Action	
Systemic	Therapies	Antimetabolites	 Methotrexate	 Inhibits	dihydrofolate	reductase	activity	which	disrupts	DNA	synthesis,	thereby	reducing	skin	cell	proliferation	Calcineurin	inhibitors	 Cyclosporine	 Down-regulates	T	cell	activity	
Biologic	Therapies	TNF	inhibitors	 Etanercept,	Infliximab,	Adalimumab	 Inhibition	of	TNF-alpha		IL-12/23	inhibitors	 Ustekinumab	 Monoclonal	antibody	that	antagonizes	IL	12	and	IL-23	IL-17	inhibitors	 Secukinumab,	Ixekizumab,	Brodalumab	 Monoclonal	antibody	against	IL-17A	Phosphodiesterase-4	inhibitor	 Apremilast	 Increases	intracellular	cAMP;	exact	mechanism	of	therapeutic	effect	unknown			
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Natural	history	studies	and	clinical	trials	have	helped	scientists	to	better	understand	how	the	complex	process	of	inflammation	translates	to	cardiovascular	disease.		To	this	end,	psoriasis,	in	particular,	has	emerged	as	a	useful	human	clinical	model	for	studying	the	development	of	cardiometabolic	diseases	such	as	atherosclerosis,	hypertension,	diabetes	mellitus,	and	dyslipidemia.		The	prevalences	of	these	comorbid	conditions	have	been	shown	to	be	elevated	in	psoriasis,	often	in	a	dose-dependent	fashion,	with	rates	seen	to	increase	with	increasing	severity	of	psoriasis.(19)		Similarly,	risk	of	myocardial	infarction	has	been	shown	to	exhibit	a	dose-dependent	increase	in	psoriasis.		In	one	Danish	population-based	study,	rate	ratios	for	all-cause	mortality,	cardiovascular	mortality,	myocardial	infarction	and	stroke	were	elevated	in	psoriasis.		Rate	ratios	of	cardiovascular	death	were	found	to	be	1.14	and	1.57	in	mild	and	severe	psoriasis,	respectively.(20)		In	addition	to	psoriasis	severity,	disease	onset	was	also	found	to	associate	with	cardiovascular	risk.		Increased	rate	ratios	of	cardiovascular	events	were	found	to	associate	with	earlier	onset	of	psoriasis,	suggesting	that	disease	exposure	promotes	progression	of	atherosclerosis	over	time	and,	thereby,	further	supporting	the	causal	link	between	psoriasis	and	cardiovascular	disease.	Psoriasis	provides	the	ideal	system	within	which	to	study	the	progression	of	cardiovascular	disease	for	several	reasons.		Firstly,	psoriasis	is	a	chronic	condition	that	is	managed	over	the	course	of	a	lifetime.		Patients,	therefore,	experience	significant	exposures	that	can	be	studied	over	longer	terms	and	which	can	be	related	to	outcomes	that	require	long	periods	of	time	to	develop	such	as	myocardial	infarction	and	mortality.		Secondly,	psoriasis	is	a	condition	with	highly	varied	presentations.		Severity	
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can	range	from	a	single,	small	psoriatic	patch	to	nearly	100%	body	surface	area	(BSA)	affected.		Severity	is	commonly	classified	as	mild	psoriasis	comprising	BSA	<3%,	moderate	psoriasis	comprising	BSA	of	3-10%,	and	severe	psoriasis	comprising	BSA	>10%.(21)		Another	reason	psoriasis	is	such	an	appropriate	condition	for	studying	the	intersection	of	inflammation	and	cardiovascular	disease	is	the	diversity	of	treatment	options	and	management	decisions.		Some	patients,	particularly	those	with	mild	psoriasis,	may	opt	to	receive	no	treatment.		Others	may	choose	topical	therapy	or	UV	light	to	keep	symptoms	at	bay.		Many,	particularly	patients	who	have	severe	psoriasis,	begin	stronger,	systemic	anti-inflammatory	therapies.		This	diversity	of	treatment	choices	provides	the	opportunity	to	study	atherosclerosis	in	psoriasis	within	various	contexts.		The	natural	progression	of	plaque	development	can	be	evaluated	in	the	absence	of	any	therapy	or	in	the	absence	of	systemic	therapy.		The	effect	of	systemic	anti-inflammatory	drugs	can	also	be	studied	in	psoriasis	patients.		
Psychological	Stress	and	Atherosclerosis	Psychological	stress,	is	another	condition	thought	to	play	a	role	in	promoting	atherosclerosis	and,	much	like	psoriasis,	this	connection	is	thought	to	occur,	at	least	in	part,	via	inflammation.		Psychological	stress,	often	studied	through	the	common	diagnoses	of	depression	and	anxiety,	has	a	complex	relationship	with	atherosclerosis.		However,	despite	becoming	a	major	area	of	interest	this	relationship	still	remains	poorly	characterized.		Some	of	the	early	observations	highlighting	the	link	between	stress	and	cardiovascular	disease	involve	the	documentation	of	cardiac	events	such	as	myocardial	infarction,	which	have	been	seen	to	rise	in	number	during	historical	
11	
calamities	leading	to	widespread	distress.		For	example,	directly	following	the	Northridge	Earthquake	in	Los	Angeles	in	1994,	mortality	due	to	myocardial	infarction	increased	significantly	in	individuals	who	did	not	experience	direct	physical	trauma	or	increased	physical	activity	within	the	population	located	closest	to	the	epicenter	of	the	earthquake.(22)		Mortality	due	to	other	cardiac	causes,	such	as	cardiomyopathy,	valvular	heart	disease	and	stroke,	did	not	change	significantly	after	the	earthquake.		Similarly,	mortality	due	to	non-cardiovascular	causes	was	unchanged	following	the	earthquake,	ultimately	leading	researchers	to	conclude	that	distressing	events	can	insight	acute	coronary	syndromes.			Chronic	states	of	stress	like	depression	also	demonstrate	a	reliable	association	with	cardiovascular	disease	in	large	population-based	studies,	so	much	so,	that	many	believe	depression	should	be	formally	considered	a	cardiovascular	risk	factor.		There	are	many	different	mechanisms	by	which	depression	is	thought	to	promote	cardiovascular	disease.(23)		Depression	associates	with	detrimental	behaviors	such	as	alcoholism,	sedentary	lifestyle,	and	suboptimal	dieting.		Although	the	influence	of	behavioral	and	environmental	factors	is	logical,	it	does	not	fully	explain	why	cardiovascular	disease	risk	is	increased	in	depression.		Among	young,	healthy	adult	populations,	a	strong	association	has	been	demonstrated	between	a	clinical	diagnosis	of	depression	and	ischemic	heart	disease	beyond	adjustment	for	traditional	cardiovascular	risk	in	the	form	of	Framingham	scores.(24)		Other	causal	mechanisms	posited	include	inflammation,	up-regulation	of	pro-thrombotic	mediators,	oxidative	stress,	and	endothelial	dysfunction.				
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	 Several	of	the	key	pathways	thought	to	mediate	the	relationship	between	psychological	stress	and	atherosclerosis	have	been	examined.		Up-regulation	of	the	sympathetic	nervous	system	occurs	under	stress	and	leads	to	the	systemic	release	of	catecholamines	such	as	epinephrine	and	norepinephrine.		These	catecholamines	promote	cardiovascular	effects	commonly	associated	with	the	stress	response,	such	as	increases	in	vascular	tone,	cardiac	contractility,	heart	rate	and	heart	rate	variability,	as	well	as	evolutionarily	adaptive	metabolic	responses	like	lipolysis	and	insulin	resistance.(25)		All	of	these	changes	are	adaptive	in	the	short-term,	when	high-risk	situations	necessitate	heightened	metabolic	activity	or	swift	physical	response,	but	in	chronic	states	of	stimulation,	either	by	external	stressors	or	psychological	dysfunction,	these	processes	become	maladaptive	and	promote	vascular	dysfunction	and	cardiometabolic	disease.		The	hypothalamic-pituitary-adrenal	(HPA)	axis	also	responds	to	stress	by	upregulating	cortisol	release.		The	resultant	chronically	elevated	levels	of	cortisol	ultimately	promote	thrombosis(26)	and	endothelial	dysfunction.(27)		Cortisol,	along	with	catecholamines	released,	lead	to	increases	in	C-reactive	protein	and	IL-6.		In	multiple	investigations	the	inflammatory	mediators,	TNF-alpha	and	IL-6	have	demonstrated	strong	associations	with	depression.(28)		Therefore,	psychological	stress	is	intricately	linked	to	cardiovascular	disease	by	multiple	physiological	mechanisms.								
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Figure	2:		Proposed	Mechanisms	Linking	Stress	to	Cardiovascular	Disease	
	
	
	
Multiple	pathways	link	the	stress	response	to	inflammation	and	cardiometabolic	diseases	including	the	HPA	axis	and	the	sympathetic	nervous	system.	
Reprinted	from	Brotman	et	al.		The	cardiovascular	toll	of	stress.		Lancet.		2007.	
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Psoriasis	and	Mood	Disorders		 In	addition	to	being	marked	by	higher	cardiovascular	risk,	psoriasis	is	also	known	to	elevate	the	risk	of	depression	and	anxiety.		One	population-based	study	from	the	United	Kingdom	identified	higher	rates	of	depression,	anxiety	and	suicidality	among	patients	with	psoriasis.(29)		After	controlling	for	age,	sex,	and	other	comorbid	conditions	such	as	obesity,	hypertension,	diabetes,	hyperlipidemia,	and	cancer,	the	adjusted	hazard	ratios	comparing	psoriasis	to	non-psoriasis	controls	were	1.39,	1.31	and	1.44	for	depression,	anxiety	and	suicidality,	respectively.		Similar	to	what	was	seen	in	studies	examining	the	relationship	between	psoriasis	and	cardiovascular	risk,	psoriasis	was	shown	to	exhibit	a	dose-dependent	relationship	with	risk	of	depression.		Additionally,	a	significant	age	interaction	was	identified,	showing	that	younger	psoriasis	patients	experienced	the	greatest	risk	for	depression.		There	is	also	evidence	to	suggest	that	the	psychological	repercussions	of	psoriasis	are	greater	for	younger	patients.		Early-onset	psoriasis,	namely	psoriasis	that	present	in	ages	<	20	years,	associates	with	increased	severity	of	both	depression	and	anxiety	when	compared	to	those	for	whom	psoriasis	presents	at	an	older	age.(30)		Patients	with	psoriasis,	therefore,	stand	to	benefit	greatly	from	targeted	mental	health	screening	and	care	that	is	cognizant	of	the	psychological	comorbidities	that	accompany	the	condition.				 While	depression	and	anxiety	often	go	hand-in-hand	with	psoriasis,	specific	therapies	for	the	treatment	of	psoriasis	can	help	to	improve	these	comorbidities.		Ustekinumab	is	a	monoclonal	antibody	that	targets	interleukins	12	and	23,	two	cytokines	known	to	play	a	central	role	in	the	pathophysiology	of	psoriasis.		In	one	
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randomized	control	trial,	it	was	shown	that	administration	of	ustekinumab,	when	compared	to	placebo,	resulted	in	improvements	in	standardized	scores	for	symptoms	of	anxiety	and	depression.(31)		One	might	expect	that	as	psoriasis	symptoms	are	alleviated,	symptoms	of	depression	and	anxiety	should	also	improve.		Interestingly,	however,	there	are	some	scientists	who	purport	that	the	relationship	between	psoriasis	and	mood	disorders	is	bidirectional	rather	than	unidirectional.		Although	there	is	little	in	the	way	of	direct	evidence	to	demonstrate	that	depression	or	psychological	stress	drives	the	onset	of	psoriasis,	patients	often	recount	that	psoriasis	onset	and	or	flares	can	occur	in	the	setting	of	significant	life	stress.		A	singular,	but	persuasive	example	of	this	is	the	case	of	a	28-year	old	woman	with	schizoaffective	disorder	in	whom	psoriasis	flares	closely	coincided	with	acute	worsening	of	her	mood	and	mental	state.(32)		Another	study	observed	that	patients	reporting	stressful	life	events	were	more	likely	to	be	experiencing	active	spread	of	psoriatic	lesions.(33)				 Due	to	the	increased	risk	of	cardiovascular	disease	coupled	with	an	increased	burden	of	psychological	stress	and	mood	disorders,	patients	with	psoriasis	represent	an	especially	high-risk	population	for	the	progression	of	atherosclerosis	and	development	of	adverse	cardiovascular	events.		At	the	intersection	of	these	comorbid	conditions	lies	a	complex	entanglement	of	causal	factors,	the	contributions	of	which	still	need	to	be	better	clarified.		For	now,	what	we	do	know	is	that	patients	with	psoriasis	who	suffer	from	comorbid	depression	experience	the	highest	rates	of	myocardial	infarction,	stroke	and	cardiovascular	death.(34)		How	much	of	this	is	due	to	behavioral	factors,	genetic	predisposition,	or	physiological	processes	set	in	motion	by	the	inflammatory	insults	of	psoriasis	or	depression	is	unknown	as	our	current	
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understanding	of	the	ways	in	which	chronic	inflammation	and	depression	interact	to	accelerate	atherosclerosis	is	not	yet	well-developed.		 Patients	with	psoriasis	represent	a	particularly	high-risk	population	for	the	development	of	cardiovascular	disease	due	to	the	“double-whammy”	of	chronic	inflammation	and	higher	rates	of	depression	and	anxiety.	Aortic	vascular	inflammation	as	measured	by	18-FDG	PET/CT	has	been	previously	used	as	a	measure	of	subclinical	vascular	disease	and	has	been	correlated	with	future	cardiovascular	events.(35)		Coronary	computed	tomography	angiography	provides	a	validated,	non-invasive	tool	for	quantifying	coronary	plaque	burden	and	is	similarly	correlated	with	future	cardiovascular	events.(36)		Amygdala	activity,	quantified	by	FDG	PET/CT,	has	also	been	validated	as	a	biological	measure	of	psychological	stress.(37)		These	non-invasive	imaging	modalities	provide	a	useful	way	to	examine	the	progression	of	atherosclerosis	in	patients	with	chronic	inflammation	and	better	understand	the	effects	of	comorbid	psychological	stress	on	subclinical	cardiovascular	disease	in	this	high-risk	population.											
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Statement	of	purpose	
Specific	Aims		The	goal	of	this	study	was	to	evaluate	the	degree	of	subclinical	vascular	disease	and	vascular	dysfunction	associated	with	self-reported	depression	as	well	as	amygdala	activity	in	a	well-phenotyped	cohort	of	psoriasis	patients.		
Hypothesis			In	this	population,	we	hypothesized	that	patients	who	reported	comorbid	depression	would	experience	greater	vascular	inflammation	and	coronary	plaque	burden	beyond	what	is	attributable	to	traditional	cardiovascular	risk.		Furthermore,	we	hypothesized	that	the	degree	of	metabolic	activity	in	the	region	of	the	amygdala	would	associate	with	increased	vascular	inflammation	and	decreased	vascular	function	in	patients	with	psoriasis.											
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Methods	
Patient	Selection	The	patient	cohort	for	this	study	was	derived	from	a	larger	psoriasis	patient	cohort	used	to	study	the	relationship	between	psoriasis	and	cardiovascular	health	at	the	National	Institutes	of	Health	(NCT01778569).		Patients	were	recruited	via	flyers	and	advertisement	at	local	dermatology	clinics	to	the	protocol	13-H-0065	beginning	on	January	23,	2013	and	continuing	until	October	14,	2015.		Prior	to	the	recruitment	of	patients,	approval	for	this	research	was	granted	by	the	Institutional	Review	Board	for	the	National	Heart	Lung	and	Blood	Institute.		All	enrolled	patients	provided	informed	consent	before	participating	in	this	study.			Patients	over	the	age	of	18	years	who	had	a	diagnosis	of	psoriasis	made	by	a	dermatologist	or	a	collaborating	board-certified	physician	were	included	in	this	study.		Exclusion	criteria	included	pregnancy,	women	currently	lactating,	and	kidney	disease	with	an	estimated	glomerular	filtration	rate	less	than	30mL/min/1.73m2.		Upon	enrollment	patients	were	seen	at	the	National	Institutes	of	Health	Clinical	Research	Center	for	a	baseline	visit.		During	this	visit	a	detailed	history	and	physical	exam	were	performed.		Several	questionnaires	were	also	administered	to	gather	key	details	and	data	on	potential	covariates.		In	one	of	these	baseline	medical	questionnaires,	study	participants	were	asked	to	report	a	history	of	depression,	anxiety,	or	other	psychiatric	illness	as	defined	by	the	use	of	medications	and/or	counseling	services.		In	total,	36	patients	reported	a	history	of	depression.		These	patients	were	then	matched	by	age	and	sex	to	36	psoriasis	patients	who	reported	no	history	of	psychiatric	illness	on	the	same	questionnaire.			
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Clinical	Assessment	All	clinical	assessments	and	scans	were	completed	at	the	National	Institutes	of	Health	Clinical	Research	Center.		At	their	baseline	visits,	all	patients	received	FDG	PET/CT	scans.		Patients	who	provided	their	consent	and	who	did	not	have	any	contraindications	to	IV	contrast	also	received	coronary	CT	angiograms.		Patients	who	consented	and	did	not	have	contraindications	to	MRI	also	underwent	FDG	PET/MRI	scanning.		All	patients	provided	blood	samples	to	be	analyzed	in	the	laboratory	for	immunologic	and	lipid	profiling.		Fasting	blood	samples	were	drawn	during	the	baseline	visit	and	immediately	sent	to	an	on-site	certified	research	laboratory	for	processing.		Key	measurements	included	levels	of	glucose,	insulin,	triglycerides,	LDL,	HDL,	total	cholesterol,	CRP,	IL-6,	IL-12,	IL-17,	IL-23,	and	TNF-alpha.				
Vascular	FDG/PET	CT	Analysis	In	preparation	for	FDG	PET/CT	scans,	patients	were	asked	to	fast	overnight	prior	to	their	visits.		During	their	baseline	visits	patients	received	a	10mCi	dose	of	18-fluorodeoxyglucose	(FDG)	tracer.		Roughly	60	minutes	later	patients	were	scanned	and	PET/CT	images	were	acquired	using	a	Siemens	Biograph	mCT	PET/CT	64-slice	scanner	(Siemens	Medical	Solutions	USA,	Malvern,	PA,	USA).		PET/CT	images	were	then	processed	and	analyzed	as	1.5mm	thick	slices	in	a	dedicated	software	program	known	as	Extended	Brilliance	Workspace	(Phillips	Electronic,	NV,	USA).		On	each	1.5mm	axial	slice,	circular	contours,	known	as	regions	of	interest,	were	placed	around	the	walls	of	the	aorta	(Figure	3A).		When	placing	regions	of	interest,	adjacent	anatomic	structures	were	carefully	avoided	in	order	to	prevent	inaccurate	measurement	of	FDG	uptake.		
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Standardized	uptake	values	of	FDG	uptake	were	calculated	using	the	semi-automated	Extended	Brilliance	Workspace	program.			
Figure	3:		Plaque	imaging	by	coronary	CT	and	aortic	vascular	inflammation	by	FDG	
PET/CT																											 		A)	FDG	PET/CT	imaging	of	a	patient	with	psoriasis	and	comorbid	depression	shows	FDG	uptake	in	the	aortic	wall	indicative	of	increased	macrophage	activity	and	vascular	inflammation.	B)	CT	imaging	of	the	right	coronary	artery	of	a	patient	with	psoriasis	as	well	as	comorbid	depression	and	anxiety	is	shown	in	4	slices.		QAngio	software	delineates	the	vessel	wall	(orange	line)	and	lumen	(yellow	line)	and	shows	areas	of	increased	wall	volume	to	be	quantitated	and	characterized	(arrow).		
A	
B	
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Mean	and	maximum	standardized	uptake	values	were	then	determined	for	each	axial	slice	and,	eventually,	for	each	segment	of	the	aorta	(1=ascending,	2=aortic	arch,	3=descending,	4=suprarenal,	5=infrarenal).		Regions	of	interest	were	also	placed	around	the	lumen	of	the	superior	vena	cava,	excluding	the	vessel	wall,	on	10	consecutive	axial	slices.		A	new	variable,	known	as	the	target-to-background	ratio,	was	calculated	by	dividing	the	maximum	standardized	uptake	value	of	each	slice	by	the	mean	standardized	uptake	value	of	the	superior	vena	cava.		Target-to-background	ratio,	therefore,	represents	the	amount	of	18-FDG	uptake,	or	in	other	words,	metabolic	activity	in	the	aortic	wall	only,	excluding	the	contribution	of	luminal	activity.		
Coronary	CT	Angiography	Scanning	Patients	who	provided	informed	consent	and	were	eligible	to	receive	coronary	CT	angiography	were	scanned	using	a	320	detector	row	unit	(Aquilion	ONE	ViSION	Edition;	Toshiba	Medical	Systems,	Otawara,	Japan)	on	the	same	day	as	their	baseline	clinical	visits.		Coronary	CT	angiography	images	were	analyzed	by	an	experienced	collaborating	cardiologist.		Using	a	dedicated	software	program,	QAngio	CT	(Medis,	The	Netherlands),	scans	were	loaded	and	analyzed	to	quantify	coronary	plaque	burden	by	composition	(Figure	3B).		Total,	non-calcified,	and	dense	calcified	plaque	were	identified	based	on	pre-defined	Hounsfield	unit	ranges	and	quantified	in	the	major	coronary	vessels:	the	left	main,	left	anterior	descending,	left	circumflex	and	right	coronary	arteries.		Each	coronary	artery	was	analyzed	individually	for	total,	non-calcified	and	dense	calcified	plaque	burden	by	dividing	the	plaque	volume	of	each	artery	by	its	length.	
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Amygdala	Uptake	by	FDG	PET/CT		In	a	follow-up	study,	patients	from	the	same	psoriasis	cohort	(NCT01778569)	who	reported	on	baseline	survey	either	a	history	of	depression,	anxiety	or	both,	were	selected	(N=41).		Those	selected	patients	were	then	matched	by	age	and	sex	to	patients	from	the	same	cohort	who	reported	no	history	of	psychiatric	illness	(N=41).		Metabolic	activity	in	the	amygdala	was	quantified	by	FDG	PET/CT	using	a	dedicated	image	processing	program	(OsiriX	MD,	Geneva,	Switzerland).		Spherical	regions	of	interest	were	placed	in	the	specific	anatomic	location	of	the	amygdala	on	1.5mm	thick	axial	cuts	of	the	FDG	PET/CT	scans.		Mean	standardized	uptake	values	were	quantified	by	the	program	based	on	the	amount	of	FDG	uptake	found	within	each	region	of	interest	placed.		All	regions	of	interest	were	placed	by	the	same	analyst,	who	was	also	blinded	to	clinical	data.		In	addition	to	measuring	uptake	in	the	anatomic	location	of	the	amygdala,	standardized	uptake	values	were	also	measured	in	the	ipsilateral	temporal	lobes	in	the	same	axial	plane	to	provide	a	background	for	standardization	of	patient	scans.		The	mean	standardized	uptake	values	of	the	amygdala	were	divided	by	the	mean	standardized	uptake	values	of	the	corresponding	temporal	lobe	in	order	to	calculate	target-to-background	ratios.		Studies	have	shown	the	left	amygdala	to	be	better	correlated	with	psychological	stress.(38)		Therefore,	this	study	focused	on	findings	from	the	left	amygdala.							
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Figure	4:		FDG	PET/CT	Analysis	of	Amygdala	Activity		
			
	
Aortic	Distensibility	by	Phase	Contrast	MRI	Aortic	distensibility	was	also	used	in	this	study	as	a	measure	of	vascular	function.		Distensibility	of	the	aorta	was	determined	by	placing	contours	on	the	walls	of	the	descending	aorta	on	axial	slices	of	the	phase	contrast	MRI	scans	throughout	the	entirety	of	one	cardiac	cycle.		A	different	analyst	who	was	also	blinded	to	clinical	data	performed	all	aortic	contouring	for	phase	contrast	MRI.		Distensibility	of	the	aorta	was	then	calculated	using	the	measurements	of	the	descending	aorta	on	transverse	axial	slices	throughout	the	cardiac	cycle.		The	following	formula	was	used	to	determine	distensibility:	[(maximum	area	–	minimum	area)	x	100]/[(minimum	area)	x	(pulse	pressure)].	
Regions	of	interest	are	placed	in	the	anatomic	location	of	the	amygdalae	and	adjacent	temporal	lobes	to	quantify	FDG	uptake.		
24	
Statistical	Analyses	Descriptive	statistics	were	generated	using	STATA	12.1	statistical	software	(StataCorp,	College	Station,	TX,	USA).		Skewness	and	kurtosis	measures	were	used	to	determine	whether	or	not	the	distribution	of	each	covariate	was	normal.		For	continuous	variables	that	were	normally	distributed,	the	Student’s	t-test	was	used.		For	continuous	variables	that	were	not	normally	distributed,	the	Mann-Whitney	U	test	was	used.		Comparisons	of	dichotomous	variables	were	performed	using	Fisher’s	exact	test.		Multiple	regression	analyses	were	run	to	evaluate	potential	relationships.			To	examine	the	relationship	between	depression	and	subclinical	atherosclerosis,	self-reported	depression	was	considered	the	primary	independent	variable	and	aortic	target-to-background	ratio	was	considered	the	primary	dependent	variable.		Univariable	regression	analyses	were	initially	performed	to	evaluate	the	association	between	the	primary	variables.		Total	and	non-calcified	coronary	plaque	burden	were	considered	secondary	outcomes	dependent	on	the	primary	independent	variable.		Multivariable	linear	regression	analyses	were	then	conducted	to	determine	the	relationship	between	self-reported	depression	and	target-to-background	ratio,	as	well	as	between	self-reported	depression	and	total	and	non-calcified	plaque	burden,	after	adjustment	for	traditional	cardiovascular	risk	in	the	form	of	Framingham	risk	score.		In	a	second,	follow-up	study	of	the	same	cohort,	logistic	regression	analyses	were	used	to	evaluate	the	association	between	amygdalar	target-to-background	ratio	and	aortic	target-to-background	ratio.		The	same	stastical	models	were	used	to	report	the	association	between	amygdalar	target-to-background	ratio	and	aortic	distensibility.		Beta	coefficients	and	p-values	were	given	to	report	on	the	strength	of	each	relationship	
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found.		All	of	the	statistical	analyses	performed	in	this	study	were	conducted	using	STATA	12.1	statistical	software.									
Statement	of	Work	Completed	by	the	Author	As	the	author	of	this	thesis,	I,	Tsion	Aberra,	attest	that	I	conceived	of	the	original	scientific	question	regarding	the	relationship	between	depression	and	vascular	inflammation	in	psoriasis.		I	generated	the	initial	hypothesis	and	constructed	the	patient	cohort	for	this	nested	cohort	study.		Using	the	clinical	database	from	the	larger	study,	I	selected	patients	based	on	depression/anxiety	status	reported	on	baseline	survey	and	performed	matching	by	age	and	sex	to	form	the	study	arms.		I	performed	all	statistical	analyses	using	pre-generated	data	from	the	larger	study.		Clinical	data,	aortic	FDG	PET/CT,	coronary	CT	angiography	and	phase	contrast	MRI	were	measured	and	recorded	by	other	members	of	the	laboratory.		I	was	involved	in	a	collaborative	effort	to	retrieve	and	enter	clinical	and	imaging	data	for	ongoing	patient	visits.		Under	the	guidance	of	a	collaborating	neuroradiologist,	I	placed	all	regions	of	interest	on	FDG	PET/CT	brain	scans	for	a	follow-up	study	on	the	same	cohort	of	patients.		I	included	5	patients	with	anxiety	only,	who	had	not	previously	been	included	in	order	to	increase	the	sample	size	and	expand	the	overall	scope	of	primary	question	to	include	anxiety	in	addition	to	depression.		While	placing	regions	of	interest	on	pre-specified	anatomic	locations	in	the	brain,	I	was	blinded	to	clinical	data,	as	patients	were	de-identified	and	given	new	tracking	numbers	during	this	process.		I	performed	all	statistical	analyses	for	this	follow-up	study.					
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Results	Patients	in	both	study	groups	were	similar	in	age	(overall	average	age=	48.9	years)	and	gender	distribution	(50%	male	in	each	group).		In	both	groups	patients	had	low	Framingham	risk	scores	on	average	and	mild-to-moderate	psoriasis	as	measured	by	Psoriasis	Area	and	Severity	Index	scores	(Table	2).		Major	clinical	parameters	and	cardiovascular	risk	factors,	such	as	hypertension,	diabetes,	hyperlipidemia	and	family	history	of	coronary	artery	disease	did	not	differ	significantly	between	groups.					In	psoriasis	patients	who	reported	a	history	of	depression,	vascular	inflammation,	as	assessed	by	FDG	PET/CT	target-to-background	ratio,	was	significantly	higher	than	in	psoriasis	patients	who	reported	no	history	of	psychiatric	illness	(Table	3A).		After	adjustment	for	Framingham	risk	scores,	these	differences	remained	significant	(Table	4A).		In	patients	using	systemic	or	biologic	anti-inflammatory	therapies,	the	relationship	between	self-reported	depression	and	aortic	vascular	target-to-background	ratio	did	not	retain	significance.		However,	in	patients	who	did	not	use	systemic	or	biologic	anti-inflammatory	therapies,	an	even	stronger	relationship	was	observed	between	depression	and	aortic	target-to-background	ratio,	than	was	seen	in	the	overall	cohort	(Table	5).			Patients	with	self-reported	depression	were	found	to	have	significantly	higher	total	and	non-calcified	coronary	plaque	burden,	assessed	by	coronary	CT	angiography	(Table	3B).		After	adjustment	for	Framingham	risk	scores	the	relationship	between	depression	and	both	total	and	non-calcified	coronary	plaque	burden	remained	statistically	significant	(Table	4B).		In	patients	using	systemic	or	biologic	therapies,	these	relationships	did	not	retain	significance,	while	in	patients	who	were	not	using	
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systemic	or	biologic	therapies,	even	stronger	relationships	between	depression	and	both	total	and	non-calcified	coronary	plaque	burden	were	observed	(Table	5).		No	significant	differences	were	observed	between	study	groups	for	dense	calcified	coronary	plaque	burden.																					
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Table	2:	Patient	Characteristics	Parameters	 Psoriasis	with	depression,	N=36	 Psoriasis	without	depression,	N=36	 P		Demographics	and	clinical	history	Age	(years)	 48.7	±	12.4	 49.0	±	12.3	 matched	Males,	N	(%)	 18	(50%)	 18	(50%)	 matched	Body	Mass	Index	 30.0	±	6.6	 28.5	±	4.7	 0.13	Hypertension,	N	(%)	 13	(36%)	 7	(19%)	 0.11	Type	2	diabetes,	N	(%)	 3	(8%)	 3	(8%)	 1.00	Hyperlipidemia,	N	(%)	 17	(47%)	 17	(47%)	 1.00	Current	tobacco	use,	N	(%)	 7	(19%)	 7	(19%)	 0.17	Personal	history	of	CAD,	N	(%)	 2	(6%)	 3	(8%)	 0.64	Family	history	of	CAD,	N	(%)	 11	(31%)	 15	(42%)	 0.33	Exercise	frequency	≥	once	weekly,	N	(%)*	 29	(88%)	 29	(94%)	 0.44	Cardiovascular	risk	profile	Systolic	BP,	mmHg	 125.5	±	19.0	 120.2	±	14.7	 0.10	Diastolic	BP,	mmHg	 74.1	±	10.2	 71.3	±	10.3	 0.13	Total	cholesterol,	mmol/L	 4.79	±	1.03	 4.57	±	0.99	 0.18	LDL	cholesterol,	mmol/L	 2.75	±	0.84	 2.56	±	0.79	 0.17	HDL	cholesterol,	mmol/L	 1.35	±	0.42	 1.44	±	0.43	 0.17	Framingham	Risk	score	[median	(IQR)]	 4	(1-6)	 2.5	(1-5)	 0.56	Hs-CRP,	nmol/L	[median	(IQR)]	 20.95	(9.71-41.43)	 22.86	(6.67-62.86)	 0.84	Psoriasis	characteristics	Disease	duration,	years	 22.3	±	15.5	 20.5	±	15.3	 0.31	Body	surface	area	affected,	%	[median	(IQR)]	 4.5	(2.8-17.4)	 3.4	(1.7-13.2)	 0.34	PASI	score	[median	(IQR)]	 6.3	(3.2-13.7)	 4.7	(2.8-12.8)	 0.25	Systemic	or	biologic	therapy,	N	(%)	 12	(33%)	 14	(39%)	 0.62		 Continuous	variables	are	expressed	as	Mean	±	Standard	Deviation	unless	specified	otherwise.	Hs-CRP	.	High	sensitivity	C-reactive	protein,	PASI	.	Psoriasis	Area	and	Severity	Index.		*N	=	33	vs.	31.		
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Table	3:		Markers	of	Subclinical	Atherosclerosis.		(A)	Vascular	Inflammation	by	
Depression	Status.		(B)	Coronary	Plaque	Burden	by	Depression	Status	Parameter	 Comorbid	depression	 No	psychiatric	history	 P		A	Vascular	inflammation	by	FDG-PET/CT	Total	aortic	TBR	 1.82	±	0.34	 1.66	±	0.18	 0.008	
Aortic	arch	TBR	 1.98	±	0.36	 1.84	±	0.21	 0.02	
Descending	aortic	TBR	 1.81	±	0.37	 1.65	±	0.18	 0.01	
	Suprarenal	aortic	TBR	 1.90	±	0.42	 1.69	±	0.24	 0.007	
	Infrarenal	aortic	TBR	 1.79	±	0.40	 1.59	±	0.19	 0.003	
	B	Plaque	burden	adjusted	for	luminal	attenuation	Total	burden	(x	100),	mm2	[median	(IQR)]	 1.11	(0.85-1.49)	 0.98	(0.81-1.22)	 0.04	
	
Non-calcified	burden	(x	100),	mm2	[median	(IQR)]	 1.10	(0.83-1.45)	 0.93	(0.78-1.21)	 0.03	
	
Dense	calcified	burden	(x	100),	mm2	[median	(IQR)]	 0.01	(0.005-0.03)	 0.01	(0.003-0.03)	 0.37		
TBR=	Target-to-Background	Ratio.	
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Table	4:		Multivariate	Analyses	of	(A)	Vascular	Inflammation	and	(B)	Coronary	
Plaque	Burden	by	Depression	Status.		Model	 β	(95%	Confidence	Interval)	 P	A	Total	aorta						Unadjusted		 0.28		(0.032-	0.290)	 0.02						Adjusted	for	FRS		 0.26		(.022-	0.280)				 0.02	Aortic	arch						Unadjusted		 0.25		(0.010-	0.287)	 0.04						Adjusted	for	FRS		 0.23		(0.002-	0.282)	 0.047	Descending	aorta						Unadjusted		 0.27		(0.022-	0.288)	 0.02						Adjusted	for	FRS		 0.25		(0.009-	0.275)	 0.03	Suprarenal	aorta						Unadjusted		 0.29		(0.045-	0.367)	 0.01						Adjusted	for	FRS		 0.27		(0.035-	0.360)		 0.02	Infrarenal	aorta						Unadjusted	 0.32		(0.058-	0.351)		 0.007						Adjusted	for	FRS		 0.30		(0.054-	0.350)		 0.01	B	Total	plaque	burden						Unadjusted		 0.18		(0.0005-	0.005)		 0.02						Adjusted	for	FRS		 0.17		(0.0002-	0.005)				 0.03	Non-calcified	burden						Unadjusted		 0.18			(0.0005-	0.005)	 0.02						Adjusted	for	FRS		 0.17		(0.0003-	0.005)		 0.03	
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Table	5:		Stratified	analysis	of	use	of	systemic/biologic	therapies.	(A)	Vascular	
inflammation,	coronary	plaque	burden	and	depression	status	relationship	
stratified	by	systemic/biologic	therapy	use.	(B)	Multivariate	analyses	stratified	
by	systemic/biologic	therapy	use.	
	A	 No	systemic/biologic	(N=46)	 Systemic/biologic	(N=26)	Parameter	 Dep	(N=24)	 No	Dep	(N=22)	 p-value	 Dep	(N=12)	 No	Dep	(N=14)	 P	Aortic	TBR	 1.85	±	0.37	 1.61	±	0.14	 0.003	 1.75	±	0.28	 1.73	±	0.21	 0.42		Total	plaque	burden	 1.46	±	1.12	 1.05	±	0.35	 0.006	 1.11	±	0.32	 1.11	±	0.46	 0.49		Non-calcified	burden	 1.42	±	1.10	 1.02	±	0.36	 0.006	 1.09	±	0.31	 1.09	±	0.46	 0.49		Dep=	Self-reported	Depression.										
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B	 No	systemic/biologic	 Systemic/biologic		Model	 β	(95%	CI)	 P	 β	(95%	CI)		 P	Relationship	between	total	aortic	vascular	inflammation	and	self-reported	depression	Unadjusted	 0.39		0.071-	0.421)	 0.007	 0.04		(-0.179-	0.219)		 0.84	Adjusted	for	FRS	 0.40		(0.073-	0.422)	 0.007	 -0.09		(-0.223-	0.144)		 0.64	Adjusted	for	FRS	and	PASI	score	 0.30		(0.024-	0.344)	 0.03	 -0.11		(-0.251-	0.573)	 0.57	Relationship	between	total	plaque	burden	and	self-reported	depression	Unadjusted	 0.24	(0.0009-	0.007)		 0.01	 0.002	(-0.002-	0.002)			 0.98	Adjusted	for	FRS	 0.23	(0.0008-	0.007)			 0.02	 -0.03	(-0.002-	0.002)	 0.79	Adjusted	for	FRS	and	PASI	score	 0.23	(0.0007-	0.007)			 0.02	 -0.07	(-0.003-	0.002)		 0.62	Relationship	between	non-calcified	plaque	burden	and	self-reported	depression	Unadjusted	 0.24	(0.0009-	0.007)		 0.01	 0.002	(-0.002-	0.002)	 0.98	Adjusted	for	FRS	 0.23	(0.0008-	0.007)	 0.01	 -0.04	(-0.002-	0.002)		 0.78	Adjusted	for	FRS	and	PASI	score	 0.23	(0.0007-	0.007)	 0.02	 -0.07	(-0.003-	0.002)		 0.61	FRS=	Framingham	Risk	Score,	PASI=	Psoriasis	Area	and	Severity	Index.		 In	a	follow-up	study	evaluating	the	relationship	between	amygdala	activity	and	vascular	inflammation	as	well	as	vascular	function,	subjects	in	both	groups	had	similar	clinical	characteristics.		Patients	with	a	history	of	depression	and/or	anxiety	had	
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significantly	higher	mean	left	amygdala	activity	than	those	reporting	no	psychiatric	history	(Table	6).		On	unadjusted	linear	regression	analysis	amygdala	activity	was	associated	with	aortic	target-to-background	ratio	on	FDG	PET/CT	(β=0.26,	p=0.02).		Amygdala	activity	also	exhibited	a	strong,	inverse	relationship	with	aortic	distensibility	on	unadjusted	regression	analysis	(β=-0.50,	p<0.001).		Furthermore,	the	observed	relationship	between	amygdala	activity	and	aortic	distensibility	persisted	after	adjustment	for	Framingham	Risk	score	and	systolic	blood	pressure	(β=-0.32,	p=0.01).																	
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Table	6:		Follow-Up	Study	on	Amygdala	Activity	Patient	Characteristics	
Parameter	 Self-Reported	Psych	Diagnosis	N=41	 No	Self-Reported	Psych	Diagnosis	N=41	 P	Demographics	and	Clinical	Characteristics	Age,	years	 49.1±13.0	 49.3±12.9	 0.47	Males,	n	(%)	 20	(49)	 20	(49)	 1	Body	mass	index,	kg/m2	 30.0±6.4	 28.3±4.6	 0.08	Hypertension,	n	(%)	 14	(34)	 9	(22)	 0.22	Type-2	diabetes,	n	(%)	 4	(10)	 3	(7)	 0.69	Hyperlipidemia,	n	(%)	 20	(49)	 19	(46)	 0.83	Current	tobacco	use,	n	(%)	 7	(17)	 3	(7)	 0.18	Clinical	and	Lab	Parameters	Systolic	blood	pressure,	mm	Hg	 125.8±18.2	 120.4±14.8	 0.07	Diastolic	blood	pressure,	mm	Hg	 73.6±10.1	 72.0±10.5	 0.24	Total	Cholesterol,	mg/dL	 185.0±38.5	 179.4±38.2	 0.25	LDL	cholesterol,	mg/dL	 106.1±32.0	 97.1±32.7	 0.11	
HDL	cholesterol,	mg/dL	 50.6±16.0	 58.8±19.4	 0.02	
Triglycerides,	mg/dL	 115	(90-179)	 92	(76-119)	 0.02	Framingham	risk	score	 4	(1-6.5)	 2	(1-4)	 0.31	HOMA-IR	 3.4	(1.6-5.6)	 2.6	(1.7-3.6)	 0.28	Apolipoprotein	A,	mg/dL	 152.7±27.9	 159.9±34.3	 0.15	Apolipoprotein	B,	mg/dL	 92.9±19.0	 87.0±20.1	 0.09	Psoriasis	Characteristics	Disease	duration,	years	 22.2±14.7	 20.3±15.6	 0.29	PASI	score	 5.4	(3.1-12.3)	 5.1	(2.8-12.8)	 0.46	Amygdala	Target-to-Background	Ratio	
Left	Amygdala	TBR	 0.85±0.09	 0.81±0.09	 0.01	Values	are	reported	as	mean±S.D.	or	median	(IQR)	for	continuous	variables	and	as	N	(%)	for	categorical	variables.	P	values	are	calculated	by	student’s	t-test	or	Mann-Whitney	U-test	for	continuous	variables	depending	on	the	normality	and	by	Pearson’s	chi-square	test	for	categorical	variables.	HOMA-IR=Homeostatic	Model	Assessment	of	Insulin	Resistance,	PASI=Psoriasis	Area	Severity	Index,	TBR=Target-to-Background	Ratio.	
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Discussion	
Context	and	Significance	This	study	is	the	first	to	evaluate	the	association	between	self-reported	depression	and	vascular	inflammation	in	patients	with	the	chronic	inflammatory	disorder,	psoriasis.		We	show	that	psoriasis	patients	who	report	comorbid	depression	experience	significantly	increased	vascular	inflammation,	total	coronary	plaque	burden,	and	non-calcified	coronary	plaque	burden.		We	also	show	that	these	observed	increases	exist	after	adjustment	for	Framingham	risk,	suggesting	that	depression	itself	may	play	a	role	in	promoting	subclinical	atherosclerosis	beyond	what	is	attributable	to	traditional	cardiovascular	risk.	A	stratified	analysis	of	the	patient	cohort	revealed	that	the	relationship	seen	between	self-reported	depression	and	markers	of	subclinical	atherosclerosis	is	stronger	in	the	absence	of	systemic	or	biologic	treatment	and	diminished	by	the	use	of	these	anti-inflammatory	therapies.		These	findings	suggest	that	anti-inflammatory	therapy	may	modify	the	relationship	between	depression	and	cardiovascular	disease	in	psoriasis.		Overall,	the	results	of	this	study	support	the	notion	that	patients	with	psoriasis,	who	are	already	at	increased	cardiovascular	risk	due	to	chronic	inflammation,	incur	even	greater	risk	with	comorbid	depression	that	is	not	attributable	to	traditional	cardiovascular	risk	factors.		Careful	screening	for	psychiatric	comorbidities	and	provision	of	appropriate	mental	health	care	for	patients	with	psoriasis	may	be	warranted	for	further	prevention	of	atherosclerosis.			Over	the	years,	several	studies	have	pointed	at	depression	as	a	causal	factor	in	cardiovascular	disease.(39,40)		Depression	has	been	shown	to	correlate	with	
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myocardial	infarction,	stroke	and	sudden	death.(41,42)		Both	depression	and	anxiety	have	been	associated	with	atherosclerosis,	although	to	differing	degrees.		Therefore,	we	chose	to	include	patients	who	reported	suffering	from	both	depression	and	anxiety	concurrently,	in	addition	to	patients	reporting	depression	alone.		Nonetheless,	it	is	important	to	keep	in	mind	that	causal	mechanisms	are	complex	and	may	differ	between	the	two	mood	disorders	in	terms	of	their	impact	on	atherosclerosis.	As	cardiovascular	imaging	techniques	have	improved,	availability	of	accurate,	non-invasive	modalities	have	led	to	a	greater	focus	on	early	markers	of	cardiovascular	disease.		These	modalities	allow	us	to	better	understand	the	process	of	atherosclerosis	as	it	occurs,	before	the	onset	of	devastating	cardiovascular	events.		The	existing	literature	examining	psychological	stress	as	an	independent	driver	of	atherosclerosis	is	small,	but	growing.		The	data	we	do	have	seem	to	support	the	idea	that	psychological	stress	promotes	atherosclerosis	and	that	this	process	is	at	least	in	part	mediated	by	inflammation.		The	results	from	this	study	lend	further	support	to	the	existing	evidence	by	showing	that	subclinical	cardiovascular	disease	is	increased	in	psoriasis	patients	with	self-reported	depression	beyond	what	is	attributable	to	traditional	cardiovascular	risk.					In	a	subsequent	study	of	a	similar	patient	population	we	follow-up	our	previous	results	by	quantifying	psychological	stress	using	amygdala	uptake	of	FDG	on	FDG	PET/CT	scans	of	the	brain.		A	recent	study	of	293	healthy	patients	conducted	at	Massachusetts	General	Hospital	demonstrated	a	robust	relationship	between	amygdala	activity	and	cardiovascular	events,	bone	marrow	activity	and	arterial	inflammation.(43)		Our	follow-up	study	reinforces	and	expands	upon	the	findings	from	this	recent	study	
37	
conducted	in	a	low-risk	population	of	patients	without	coronary	artery	disease.		We	are	able	to	show	in	a	psoriasis	population	that	both	that	left	amygdala	FDG	uptake	target-to-background	ratio	is	increased	in	patients	who	report	a	history	of	depression	and/or	anxiety,	and	that	these	patients	experience	greater	vascular	inflammation	and	decreased	vascular	function.		Furthermore,	we	go	on	to	show	that	vascular	function	remains	significantly	associated	with	left	amygdala	uptake	after	adjustment	for	Framingham	risk,	suggesting	that	the	extent	of	vascular	dysfunction	cannot	be	fully	attributed	to	traditional	cardiovascular	risk.		These	findings	further	underscore	the	impact	of	psychological	stress	on	cardiovascular	disease.		In	this	study	we	are	able	to	observe	the	atherosclerotic	process	at	an	earlier	stage	in	the	natural	history,	but	where	vulnerable	patients	already	begin	to	diverge	from	their	counterparts	with	less	psychological	burden.						
Strengths	and	Limitations		 The	strengths	of	this	study	are	that	it	uses	a	deeply-phenotyped	cohort	of	patients,	validated	non-invasive	cardiovascular	imaging	modalities	are	used	to	examine	intermediate	outcomes,	and	that	psychological	stress	is	examined	in	two	different	ways:	self-reported	diagnosis	and	imaging	of	the	amygdala,	a	region	of	the	brain	involved	in	processing	stress.		Limitations	include	the	sample	size,	lack	of	longitudinal	data	for	follow-up	and	the	lack	of	standardized	metrics	for	quantifying	psychological	stress	such	as	depression	inventories.		In	the	future,	larger	studies	that	follow	patients	out	several	years	to	observe	the	progression	of	disease	burden	will	allow	for	a	better	
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understanding	of	the	impact	of	psychological	stress	on	atherosclerosis	in	patients	with	and	without	chronic	inflammation.							
Conclusion			 Overall,	in	this	study	we	demonstrate	that	psychological	stress	in	patients	with	the	chronic	inflammatory	disorder,	psoriasis,	associates	with	greater	subclinical	cardiovascular	disease	and	vascular	dysfunction.		Chronic	stress	may,	therefore,	play	a	key	role	in	the	development	and	progression	of	atherosclerosis	beyond	what	can	be	explained	by	links	to	detrimental	lifestyle	or	traditional	cardiovascular	risk.		As	this	is	a	small,	cross-sectional	study,	causation	cannot	be	determined	from	the	results	of	this	work,	however,	we	provide	the	basis	from	which	future	studies	may	further	evaluate	the	mechanistic	links	between	chronic	inflammation,	psychological	stress	and	cardiovascular	disease.		Furthermore,	we	identify	a	patient	population	that	is	at	even	greater	risk	of	cardiovascular	disease	through	comorbid	psychiatric	disease,	which	may	not	be	well-served	by	conventional	prognostication	methods	that	do	not	take	such	comorbidities	into	account.		Patients	who	suffer	from	psoriasis	and	other	chronic	inflammatory	diseases	may	benefit	from	better	risk	stratification	that	is	inclusive	of	psychological	stress	and	targeted	care	for	psychiatric	comorbidities	in	order	to	reduce	future	risk	of	adverse	cardiovascular	outcomes.					
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